RECHEM
Welcome to our website!|Hot Line: 86-21-31433387|E-mail: sales@rechemscience.com
Products Category
Contact Us
| Tel: | +86-21-31433387 |
| +86-15618786686 | |
| Email: | sales@rechemscience.com |
| info@rechemscience.com | |
| QQ: | 1369748377 |
| Skype: | sales@rechemscience.com |
| Cat.No. | Product name | Product Description |
| R2030056 | Alogliptin (SYR-322 free base) | Alogliptin (SYR-322 free base) is a potent, selective inhibitor of DPP-4 with IC |
| R2030057 | Aceclofenac | Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) analog of Diclofen |
| R2030058 | ASP3026 | ASP3026 is a novel and selective inhibitor for ALK (anaplastic lymphoma kinase) |
| R2030059 | Mutant EGFR inhibitor | Mutant EGFR inhibitor is a potent and selective mutant EGFR inhibitor extracted |
| R2030060 | Rociletinib hydrobromide(CO-1686 hydrobromide;AVL-301 hydrobromide;CNX-419 hydrobromide) | Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase in |
| R2030061 | JAK3-IN-1 | JAK3-IN-1 (Compound 9) is a potent, selective and orally active JAK3 inhibitor w |
| R2030062 | Amcasertib (BBI503) | Amcasertib is an orally administered investigational agent designed to inhibit c |
| R2030063 | BACE1-IN-2 | BACE1-IN-2 is a 1,4-Oxazine β-Secretase 1 (BACE1) inhibitor with an IC50 of 22 n |
| R2030064 | JNJ-678 (JNJ-53718678) | JNJ-678 (JNJ-53718678) is a novel fusion protein inhibitor in clinical trials fo |
| R2030065 | IDO-IN-8 (NLG-1487) | IDO-IN-8 (NLG-1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted |
| R2030066 | GSK2798745 | GSK2798745 is a first-in-class, highly potent, selective, orally active transien |
| R2030067 | Zoliflodacin (ETX0914; AZD0914) | Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gy |
| R2030068 | Enasidenib mesylate (AG-221 mesylate) | Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inh |
| R2030069 | CM-4620 | CM-4620 is a calcium-release activated calcium-channel (CRAC channel) inhibitor, |
| R2030070 | PF-06650833 | PF06650833 is a potent, selective and orally active inhibitor of interleukin-1 r |
| R2030071 | PF-06840003 (EOS200271) | PF-06840003 is a highly selective orally bioavailable IDO-1 inhibitor with |
| R2030072 | Agerafenib (CEP-32496; RXDX-105) | Agerafenib (CEP-32496; RXDX-105) is a highly potent and orally efficacious inhib |
| R2030073 | Capivasertib (AZD5363) | Capivasertib (AZD5363) is a potent pan-AKT kinase inhibitor with IC50 of 3, 7 an |
| R2030074 | CDM-NAG | |
| R2030075 | Miridesap (CPHPC; Ro63-8695; GSK2315698) | Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit |
| R2030076 | Afuresertib (GSK2110183) | Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive a |
| R2030077 | GSK2879552 | GSK2879552 is an orally available, irreversible inhibitor of lysine specific dem |
| R2030078 | IB-MECA acetonide | IB-MECA acetonide is an agonist of the adenosine A3 receptor with EC50 valu |
| R2030079 | IDO-IN-7;Navoximod (GDC-0919; NLG-919) | Navoximod (GDC-0919; NLG-919) is a potent IDO (indoleamine-(2,3)-dioxygenase) p |
| R2030081 | LUF6000 | LUF6000 is an allosteric modulator of the human A3 adenosine receptor (AR). IC50 |
